Bubble Bubble, Toil and Trouble – or Not?
In the wake of bursting housing and financial bubbles, it is little wonder why there is widespread speculation throughout the venture capital and private equity…
Posted by
Safeguard Insights
Taming Regulatory Reform
Many a CFO has lost more than a night’s sleep contemplating both the intended and unintended consequences of new healthcare regulations. Because of the uncertainty…
Posted by
Life Sciences Trends for 2011: Companion Diagnostics, Reimbursement and Consumerization
Last week, Safeguard Scientifics’ Life Sciences team attended J.P. Morgan’s 29th Annual Healthcare Conference and OneMedForumSF 2011 (video) in San Francisco. Our main takeaway is that…
Posted by
Challenges for Corporate CEOs in 2011
2010 was a trying year for every business. Even with the recent glimmers of economic improvement, 2011 will be no less challenging. I was recently…
Posted by
Aggregate Partner Company Revenue up 73% in Q3; Guidance Increased to between $360 Million to $385 Million
Earlier today in our third quarter results conference call, we announced that our aggregate partner company revenue increased 73 percent in Q3, and that for…
Posted by
Third Quarter 2010 Trends in Venture Capital
According to the latest MoneyTree survey conducted by PricewaterhouseCoopers and the National Venture Capital Association, venture capital investing in the third quarter of 2010 was…
Posted by
Safeguard Scientifics Investor Day 2010 Recap
Thank you to those who were able to attend Safeguard Scientifics’ Investor Day 2010 either in person or via webcast. For those of you were…
Posted by
Strong Diversification Strategy Can Thwart Grim VC Numbers
The data from Thomson Reuters/NVCA on venture capital investing over the past 10 years has sparked an onslaught of debate and media coverage highlighting the…
Posted by
The Current Competitive M&A Climate
As reported recently in The Wall Street Journal, companies are sitting on nearly $2 trillion of cash. As a result, shareholders are beginning to ask…
Posted by
